Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial

por Papadopoulos, Kyriakos P., Ben-Ami, Eytan, Patnaik, Amita, Trone, Denise, Li, Jianke, Demetri, George D.
Publicado 2018

Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors

por Papadopoulos, Kyriakos P., Lakhani, Nehal, Falchook, Gerald S., Riley, Gosia, Baeck, Johan, Brown, Karen S., Gordon, Gilad, Le, Lidya, Wang, Judy S.
Publicado 2020

A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors

por Smith, David C., Chugh, Rashmi, Patnaik, Amita, Papadopoulos, Kyriakos P., Wang, Min, Kapoun, Ann M., Xu, Lu, Dupont, Jakob, Stagg, Robert J., Tolcher, Anthony
Publicado 2018

A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors

por Papadopoulos, Kyriakos P, Tsai, Frank, Hamid, Omid, Xiao, Feng, Steele, Keith E, Rebelatto, Marlon C, Robbins, Paul B, Karakunnel, Joyson J, Lai, Dominic W, Mahipal, Amit
Publicado 2015

Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with...

por Naing, Aung, Eder, Joseph P, Piha-Paul, Sarina A, Gimmi, Claude, Hussey, Elizabeth, Zhang, Sen, Hildebrand, Vera, Hosagrahara, Vinayak, Habermehl, Christina, Moisan, Jacques, Papadopoulos, Kyriakos P
Publicado 2020

Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis

por Paccaly, Anne J., Migden, Michael R., Papadopoulos, Kyriakos P., Yang, Feng, Davis, John D., Rippley, Ronda K., Lowy, Israel, Fury, Matthew G., Stankevich, Elizabeth, Rischin, Danny
Publicado 2021

Pegilodecakin as monotherapy or in combination with anti‐PD‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohor...

por Tannir, Nizar M., Papadopoulos, Kyriakos P., Wong, Deborah J., Aljumaily, Raid, Hung, Annie, Afable, Manuel, Kim, Jong Seok, Ferry, David, Drakaki, Alexandra, Bendell, Johanna, Naing, Aung
Publicado 2021

A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors

por Papadopoulos, Kyriakos P., Burris, Howard A., Gordon, Michael, Lee, Peter, Sausville, Edward A., Rosen, Peter J., Patnaik, Amita, Cutler, Richard E., Wang, Zhengping, Lee, Susan, Jones, Suzanne F., Infante, Jeffery R.
Publicado 2013

A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors

por Tolcher, Anthony W., Rodrigueza, Wendi V., Rasco, Drew W., Patnaik, Amita, Papadopoulos, Kyriakos P., Amaya, Alex, Moore, Timothy D., Gaylor, Shari K., Bisgaier, Charles L., Sooch, Mina P., Woolliscroft, Michael J., Messmann, Richard A.
Publicado 2013

A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer

por Lush, Richard M., Patnaik, Amita, Sullivan, Daniel, Papadopoulos, Kyriakos P., Trucksis, Michele, McCrea, Jacqueline, Cerchio, Kristine, Li, Xiaodong, Stroh, Mark, Selverian, Diana, Orford, Keith, Ebbinghaus, Scot, Agrawal, Nancy, Iwamoto, Marian, Wagner, John A., Tolcher, Anthony
Publicado 2012

A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers

por Tolcher, Anthony, Flaherty, Keith, Shapiro, Geoffrey I., Berlin, Jordan, Witzig, Thomas, Habermann, Thomas, Bullock, Andrea, Rock, Edwin, Elekes, Agnes, Lin, Chester, Kostic, Dusan, Ohi, Naoto, Rasco, Drew, Papadopoulos, Kyriakos P., Patnaik, Amita, Smith, Lon, Cote, Gregory M.
Publicado 2018

CD8+ T cell stimulation with pegylated recombinant human IL-10 in the patient with advanced solid tumors - a Phase I study

por Naing, Aung, Infante, Jeffrey R, Papadopoulos, Kyriakos P, Autio, Karen A, Wong, Deborah J, Falchook, Gerald S, Patel, Manish R, Pant, Shubham, Whiteside, Melinda, Bendell, Johanna, Bauer, Todd M, Janku, Filip, Javle, Milind, Colen, Rivka, Tannir, Nizar, Oft, Martin
Publicado 2015

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

por Molife, L Rhoda, Yan, Li, Vitfell-Rasmussen, Joanna, Zernhelt, Adriane M, Sullivan, Daniel M, Cassier, Philippe A, Chen, Eric, Biondo, Andrea, Tetteh, Ernestina, Siu, Lillian L, Patnaik, Amita, Papadopoulos, Kyriakos P, de Bono, Johann S, Tolcher, Anthony W, Minton, Susan
Publicado 2014

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS(G12C) Solid Tumors (KRYSTAL-1)

por Ou, Sai-Hong Ignatius, Jänne, Pasi A., Leal, Ticiana A., Rybkin, Igor I., Sabari, Joshua K., Barve, Minal A., Bazhenova, Lyudmila, Johnson, Melissa L., Velastegui, Karen L., Cilliers, Cornelius, Christensen, James G., Yan, Xiaohong, Chao, Richard C., Papadopoulos, Kyriakos P.
Publicado 2022

Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay

por Lee, Susan J., Levitsky, Konstantin, Parlati, Francesco, Bennett, Mark K., Arastu‐Kapur, Shirin, Kellerman, Lois, Woo, Tina F., Wong, Alvin F., Papadopoulos, Kyriakos P., Niesvizky, Ruben, Badros, Ashraf Z., Vij, Ravi, Jagannath, Sundar, Siegel, David, Wang, Michael, Ahmann, Gregory J., Kirk, Christopher J.
Publicado 2016

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

por Mazzaferro, Vincenzo, El-Rayes, Bassel F., Droz dit Busset, Michele, Cotsoglou, Christian, Harris, William P., Damjanov, Nevena, Masi, Gianluca, Rimassa, Lorenza, Personeni, Nicola, Braiteh, Fadi, Zagonel, Vittorina, Papadopoulos, Kyriakos P., Hall, Terence, Wang, Yunxia, Schwartz, Brian, Kazakin, Julia, Bhoori, Sherrie, de Braud, Filippo, Shaib, Walid L.
Publicado 2018

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor

por Bendell, Johanna C, Javle, Milind, Bekaii-Saab, Tanios S, Finn, Richard S, Wainberg, Zev A, Laheru, Daniel A, Weekes, Colin D, Tan, Benjamin R, Khan, Gazala N, Zalupski, Mark M, Infante, Jeffrey R, Jones, Suzanne, Papadopoulos, Kyriakos P, Tolcher, Anthony W, Chavira, Renae E, Christy-Bittel, Janna L, Barrett, Emma, Patnaik, Amita
Publicado 2017

Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors

por Razak, Albiruni RA, Cleary, James M, Moreno, Victor, Boyer, Michael, Calvo Aller, Emiliano, Edenfield, William, Tie, Jeanne, Harvey, R Donald, Rutten, Annemie, Shah, Manish A, Olszanski, Anthony J, Jäger, Dirk, Lakhani, Nehal, Ryan, David P, Rasmussen, Erik, Juan, Gloria, Wong, Hansen, Soman, Neelesh, Smit, Marie-Anne Damiette, Nagorsen, Dirk, Papadopoulos, Kyriakos P
Publicado 2020

Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor

por Goss, Glenwood D., Vokes, Everett E., Gordon, Michael S., Gandhi, Leena, Papadopoulos, Kyriakos P., Rasco, Drew W., Fischer, JuDee S., Chu, Katharine L., Ames, William W., Mittapalli, Rajendar K., Lee, Ho‐Jin, Zeng, Jiewei, Roberts‐Rapp, Lisa A., Loberg, Lise I., Ansell, Peter J., Reilly, Edward B., Ocampo, Christopher J., Holen, Kyle D., Tolcher, Anthony W.
Publicado 2018

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study

por van den Bent, Martin, Gan, Hui K., Lassman, Andrew B., Kumthekar, Priya, Merrell, Ryan, Butowski, Nicholas, Lwin, Zarnie, Mikkelsen, Tom, Nabors, Louis B., Papadopoulos, Kyriakos P., Penas-Prado, Marta, Simes, John, Wheeler, Helen, Walbert, Tobias, Scott, Andrew M., Gomez, Erica, Lee, Ho-Jin, Roberts-Rapp, Lisa, Xiong, Hao, Bain, Earle, Ansell, Peter J., Holen, Kyle D., Maag, David, Reardon, David A.
Publicado 2017